Market Research Blog

Neurology digital therapeutics is the field of healthcare that deals with and prevents medical conditions using information and communication technology. According to the recent research by FMI, the neurology digital therapeutics market is anticipated to witness a 9.0% growth during the forecast period from 2021 to 2031. This significant growth will be experienced due to the advancement in technology in the healthcare sector. Therefore, neurology digital therapeutics demand is expected to increase significantly soon.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14231

What is Driving Demand for Neurology Digital Therapeutics?

Various factors are driving the demand for neurology digital therapeutics such as it optimizes the time of administrative tasks and routine communication, it reduces the pain associated with the traditional therapeutic methods, it make the monitoring easier and more accurate.

These technologies can also be used for therapy and rehabilitation purposes with the help of smartphones, tablets and computers.

Also, neurological digital therapeutics can overcome various problems related to traditional clinical practices. Thus, all these factors have the potential to drive the demand of the market during the forecast period from 2021 to 2031.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14231

Advancement in Information Technology Likely to Augment Neurology Digital Therapeutics

Information technology work in conjugation with the drugs to give maximum benefit of the treatment to the patients. Patients can take care of their health through easy-to-use apps and monitoring devices. Start-ups are introducing different innovative ideas to attract investors.

Also, the prevalence of chronic diseases is rising in the world that creating opportunities for healthcare and digital therapy players to invest in the market by innovating and launching technological advanced devices and enhance the neurological digital therapeutics demand globally.

The treatment of chronic diseases with the traditional method is becoming a challenging thing for healthcare workers and manufacturers due to its increasing burden. Thus, innovative technology or digital therapeutics is required for the treatment of a large number of populations suffering from chronic diseases.

Thus, it is expected to boost the market of neurology digital therapeutics during the forecast period from 2021 to 2031 in the world.

Request Brochure of Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-14231

The U.S. and Canada Neurology Digital Therapeutics Market Outlook

U.S. and Canada remain the predominant market for neurology digital therapeutics because of the presence of key players in the region. For instance, Pear Therapeutics headquartered in the U.S. operates at the intersection of biology and software technology. The company discovers, develops, and delivers clinically certified software to provide better outcomes for patients using neurological digital therapeutics.

Thus, the demand for neurology digital therapeutics will increase in the region during the forecast period from 2021 to 2031.

Europe Demand Outlook for Neurology Digital Therapeutics

The demand for neurology digital therapeutics will be increased in Europe because of a rising number of chronic disease amongst patients with rising geriatric populations in the region.

With increasing age, the chances of developing chronic diseases also increase in the region.

According to EUROSTAT, in 2020, there were 20.6% of people in Europe were more than 65 years of age.

Thus, there will be growth in the neurology digital therapeutics market in the region during the forecast period from 2021 to 2031.

Who are the Key Manufacturers and Suppliers of Neurology Digital Therapeutics?

The key players of neurology digital therapeutics include

• Livongo Health
• Noom
• Omada Health
• Pear Therapeutics
• WellDoc
• Proteus Digital Health
• Propeller Health
• Akili Interactive Labs
• Mango Health
• Better Therapeutics
• Happify
• Kaia Health
• Click Therapeutics and others.

They follow certain strategies to survive in the market like a product launch, product approval, patent gaining, expansion, acquisition and merger. For instance, in October 2021, Pear Therapeutics announced about continuing the expansion of intellectual property portfolio for prescription digital therapeutics.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-14231

Key Segments

By Product Type:

• Software
• Devices

By Indication:

• Diabetes
• Obesity
• Cardiovascular Disease (CVD)
• Central Nervous System (CNS) Disease
• Respiratory Disease
• Others

By End User:

• Hospital
• Clinics
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

Skin perfusion pressure (SPP) assess the local pressure in the microcirculatory system. It is widely used parameter in assessment of wound healing potential in patients with limb ischemia and peripheral artery diseases. SPP testing devices have become crucial for wound healing in patients with chronic limb ischemia. Future Market Insights (FMI), in a new study has forecast the market for skin perfusion pressure testing devices to exhibit 4.6% Y-o-Y growth in 2021. Driven by rising healthcare spending, the market will continue exhibiting high demand through the forecast period, from 2020 to 2030.

Compared to other non-invasive methods such as toe blood pressure and ankle-brachial index, SPP provides more accurate results, and thus, its usage is gaining popularity among physicians. It has been observed that SPP can evaluate ischemic condition of the lower extremities which cannot be assessed by ankle-brachial index. This increases the preference of SPP over ABI, which in turn is expected to drive the skin perfusion pressure testing devices market.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9263

The rising prevalence of peripheral arterial disease is another major factor driving the demand growth. Peripheral arterial disease (PAD) prevents wound healing of lower extremity. The patient populations at highest-risk have ischemic disease, foot ulcers, diabetes mellitus, and/or compromised kidney function. The most widely used test is ankle brachial index (ABI), but it has limited utility in foot ulcer patients. Ankle brachial index alone is not considered effective of wound healing. For overcoming this problem, manufacturers are focusing to develop advanced skin perfusion pressure.

The COVID-19 pandemic has significantly affected the medical practices, resulting in a decrease in non-essential medical care, including the wound healing specialty. The nationwide lockdown and disrupted supply chain has limited the ability to practice wound healing in normal conditions. The pandemic in the first few months of 2020 has had a negative impact on the skin perfusion pressure testing devices market.

Manufacturers are currently focusing on designing new innovative laser dopplers that can provide better results at less cost, and at the same time give simple and reliable outputs. For instance, free flap monitoring, a new generation device provides web-based capability, whereby, recordings from a laser doppler can be transmitted directly to a smart phone. Such advancements are expected to bode well for the global market.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-9263

Key Takeaways from Skin Perfusion Pressure Testing Devices Marker Study

• The global skin perfusion pressure testing devices market is estimated to be US$ 28.83 Mn in 2020, is expected to grow at a market CAGR of 4.5% during the forecast period (2020-2030)
• The U.S. holds over 90% share of the North America market, but Canada is projected to expand faster at around 5.0% CAGR
• Germany holds the largest share of the market in Europe, and will expand at a CAGR of around 4.8% through 2030
• The U.K. will exhibit 5.3% Y-o-Y growth in 2021, emerging as a key market for SPP testing devices in Europe. France will also continue exhibiting high demand
• Japan and South Korea are expected to emerge as key markets for SPP testing devices in East Asia

 “Growing advancements in skin perfusion pressure testing devices and rising prevalence of peripheral artery disease and chronic limb ischemia are expected to aid increasing demand for skin perfusion testing devices. Against this backdrop, manufacturers are likely to invest in innovation to facilitate advanced treatment” says the FMI Analyst

Who is Winning?

Leading players in the skin perfusion pressure testing devices market are strengthening their market position though the acquisition, partnerships and expansion. For Instance,

• In October, 2015, Vasamed Incorporated entered into a collaboration and distribution agreement with CorVascular Diagnostics, LLC, which designs and distributes peripheral vascular diagnostic solutions.
• In January 2019, Perimed AB announced a partnership with Radiometer Medical ApS (Radiometer) to accelerate and expand the distribution of Perimed PeriFlux 6000 tcpO2 standalone system.

Some of the key market players covered by FMI include Vasamed Incorporated, Moor Instruments, Perimed AB, ELCAT GmbH, ATYS Medical, Viasonix, and Promed Group, consolidating their positions through mergers, acquisitions and new product launches.

Get Customization in the Report, Enquire Now @ https://www.futuremarketinsights.com/customization-available/rep-gb-9263

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global skin perfusion pressure testing devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on skin perfusion pressure testing devices market on basis of product in detail, cover every aspects of the market such as (laser doppler skin perfusion pressure testing devices, phtoplethysmography skin perfusion pressure testing devices, and consumables), modality (portable devices, cart-based devices), and end user (hospitals, ambulatory surgical centers, wound care centers, and vascular laboratories) across seven major regions.

According to the latest research by Future Market Insights (FMI), the global retail clinics market value will exceed US$ 8 billion towards the end of 2028, reflecting a robust CAGR of more than 10% during 2018-2028. The revenue generated from the collective demand for retail clinics for point-of-care diagnostics and vaccination accounts for a whopping market value share of nearly 75%, according to FMI’s analysis.

Increasing acceptance of the retail clinics concept, rising awareness about cost related advantages, and improving government support for walk-in clinics will collectively supplement the growth of retail clinics market over the course of coming years. The report opines that the role of governments will be vital in popularization of retail clinics, particularly in developing regional markets.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-9254

Convenience & Cost Benefit Collectively Pushing Prospects of Retail Clinics

Retail clinics follow a holistic care approach. In addition, their partnership with various Telehealth vendors such as Teladoc and Doctor on Demand enable healthcare delivery and services at any given place and time. For Instance, an E-commerce channel is being implemented by the US-based CVS Health, one of the leaders in the MinuteClinic chain of retail clinics.

Preview Analysis Global Retail Clinics Market Segmentation By Service Type (Reimbursement Scenario, , Procedure Codes, Reimbursement Scenario, U.S. Patient Claim Lines, Target Population for Retail Clinics, Consumer Sentiment Analysis, Available Models for Retail Clinics, Walgreens Co., Costs Per Patient Visit Comparison); By Application (Point-of-Care Diagnostics, Clinical Chemistry & Immunoassay, Vaccination, Others): https://www.futuremarketinsights.com/reports/retail-clinics-market

Challenges to Retail Clinics Penetration Still Prevail, in Developing Regions

Developed regions, the key areas for retail clinics market, account for over 80% of the global revenue. The report envisages significant growth potential in emerging East Asian economies for the retail clinics market, over the projection period.

Retail clinics have been attracting a wide consumer base across the US and the number is actively growing in other key markets such as Europe and China. However, the outreach of retail clinics continues to face challenges due to poor monitoring of penetration into several developing as well as underdeveloped regions. While retail clinics have gained attention since the past few years and are expanding their offerings prudently at a rapid pace, the report highlights that this prompts at an increased need for regulation checks over the coming years.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-9254

Retail clinics are positioning themselves to play a crucial role in the delivery of primary care services, worldwide. This trend in the retail clinics market is expected to increase predominantly in developing regions. The potential opportunities will also create long-term challenges facing retailers, clinical laboratories, healthcare policy makers, and pathologists, as suggested by the report.

Key Players Keen on Investing Efforts in Customer Adherence

Patients face difficulties with respect to filing specialty prescriptions, which further affects their will for adherence. CVS Health also piloted a Specialty Connect Program to overcome hindrances in adherence. This program is claimed to enable patients to drop their prescriptions at any given CVS Health store and pick up their medicines once ready. The program has also initiated the delivery of these medicines at their houses or any clinician’s office.

Retail Clinics Market: Segmentation

on the basis of application

• point-of-care diagnostics
• clinical chemistry
• immunoassay
• vaccinations
• others.

on the basis of distribution channel

• retail pharmacies
• drug stores
• grocery chain
• big box stores.

on the basis of ownership type

• retail-owned retail clinics
• hospital-owned retail clinics

The endoscopic ultrasound needles market is witnessing the advent of wide range of products including technological advancements in FNA and FNB for solid lesions. Endoscopic ultrasound have gained wide acceptance among surgeons as minimally invasive procedure along with EUS guided needles as the safe and minimally invasive method driving endoscopic ultrasound needles market growth.

Exceeding the revenue of US$ 1 billion in 2018, the global sales of gastroesophageal disease devices will witness a steady over 4% CAGR during 2018-2028. As indicated in a new intelligence outlook of Future Market Insights (FMI), esphagoscopes and gastroscopes will continue to account for most of the sales. Adoption of gastroesophageal reflux disease devices will remain maximum for diagnostic procedures, followed by fundoplication procedures.

More Patients Continue to Prefer GERD Devices over Lifestyle Modifications & PPIs

Besides the rapid expansion of geriatric population and elevating prevalence rate of obesity-driven gastroesophageal reflux diseases, FMI in a new study states that the frequent intake of asthma medications is also a strong impact factor associated with the growth of gastroesophageal reflux disease devices market.

Although industry experts recommend lifestyle modifications as the most suitable remedy for gastroesophageal diseases, the growing demand for surgeries for obesity will continue to drive sales of gastroesophageal disease devices in coming years.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1741

Although industry experts recommend lifestyle modifications as the most suitable remedy for gastroesophageal diseases, the growing demand for surgeries for obesity will continue to drive sales of gastroesophageal disease devices in coming years.

The second line of treatment for gastroesophageal reflux disease includes proton pump inhibitors (PPI) therapy, which can reduce the usage of gastroesophageal reflux disease devices. Proton pump inhibitors are the drugs that regulate acid production within stomach, and thereby restrict gastroesophageal reflux.

However, the proven side effects and functional failure of proton pump inhibitors in the long run will continue to benefit the demand for surgical treatment of gastroesophageal reflux disease, favoring the overall sales of gastroesophageal reflux disease devices such as PH monitoring system and manometry system.

For More Information On This Report, Please Visit @ https://www.futuremarketinsights.com/checkout/1741

Diagnostic Centers & Private Clinics to Employ More GERD Devices

While a majority of adoption of gastroesophageal reflux disease devices prevails in hospitals, the constantly increasing number of establishments in the ambulatory surgical center and diagnostic center segments is likely to translate into a higher rate of adoption of gastroesophageal reflux disease devices within the latter two.

With the number of diagnostic centers and private practice clinics on the constant rise, it is more likely that the demand for gastroesophageal reflux disease devices will observe steady growth over the years to come. Towards the end of forecast period, global market value share of clinics and diagnostic centers will be more than 35%, as suggested by FMI’s analysis of the gastroesophageal reflux disease devices market.

Preview Analysis Global Gastroesophageal Reflux Diseases Devices Market: by Product Type – Diagnostic Devices, Manometry System, PH Monitoring System, Esophagoscopes and Gastroscopes, Treatment Devices, Ultrasonic Surgical Endostapler, Fundoplication Devices, Sphincter Augmentation Devices, Radiofrequency Ablation Devices; by Procedure Type – Diagnostic Procedures, Fundoplication Procedures, Radiofrequency Thermal Ablation, Magnetic Sphincter Augmentation: https://www.futuremarketinsights.com/reports/gastroesophageal-reflux-diseases-devices-market

Key GERD Device Manufacturers Eyeing New Product Launches

The report tracks some of the key companies operating in the Gastroesophageal Reflux Disease Devices market, such as Olympus Corporation, Pentax Medical, Medtronic Plc., Diversatek Inc. The report also tracks the key manufacturers operating in gastroesophageal reflux disease treatment devices, such as EndoGastric Solutions, Medigus Ltd., Torax Medical, Inc. and Mederi RF, Inc.

A majority of key manufacturers of gastroesophageal reflux disease devices are emphasizing new product launches. Innovation of new and advanced products is in turn shaping the growth of gastroesophageal reflux disease devices market.

According to the report findings,

• Olympus Corporation and Pentax Medical hold the maximum company share in the gastroesophageal reflux disease devices market.
• Olympus Corporation recently launched an advanced version of esophagoscope and gastroscope.
• Plc. and Diversatek, Inc. are the key players of diagnostic devices for gastroesophageal reflux disease, contributing a significant share in overall gastroesophageal reflux disease devices market.
• EsophyX Z is the new and advanced version of EsophyX gastroesophageal reflux disease device, used for the transoral incisionless fundoplication process.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1741

More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:

• Pharma And Healthcare Social Media Marketing Market Analysis
• Medical Device Technologies Market Analysis
• Sleep Aid Devices Market Analysis

The growth of weight loss and obesity management market is attributed to the rising epidemic of obesity across the globe. According to the latest research by Future Market Insights (FMI), the global weight loss and obesity management market is anticipated to reach a valuation of over US$ 4.9 Bn, by the end of 2028. The weight loss and obesity management market is expected to expand at a steady CAGR of 5.2%, over the forecast period of 2018-2028.

Developing Regions More Prone to Obesity & Other Comorbidities

Key Players:

• Novo Nordisk A/S,
• GlaxoSmithKline plc.,
• F. Hoffmann-La Roche AG,
• Allergan Plc,
• Johnson & Johnson Services, Inc,
• Medtronic plc.,
• Vivus Inc.,
• Eisai Co., Ltd.,
• ReShape Lifesciences, Inc,
• Obalon Therapeutics,
• Aspire Bariatrics,
• Allurion Technologies Inc.,
• Nalpropion Pharmaceuticals, Inc., and
• Beijing Noble Laser Technology Co., Ltd.

Key Vendors Targeting Extension of Product Portfolio

Leading companies operating in weight loss and obesity management market are majorly focusing on strengthening their product portfolio. Product line extensions help companies to launch newer products with unique features for specific indications. This results in an increased market share of companies in the highly competitive weight loss and obesity management market. In response to increasing demand from various healthcare professionals to effectively treat obesity with minimum long-term side effects, manufacturers are focusing on developing innovative and specific products.

Product innovation is expected to boost revenue and volume growth of the weight loss and obesity management market during the forecast period. For instance, an additional FDA patents approval for VIVUS, Inc.’s Qsymia, for the covering compositions of Qsymia and covering methods for effecting weight loss using Qsymia (phentermine and topiramate).

However, the high cost involved in research and development of obesity drugs is a great challenge for the growth of the weight loss and obesity management market. Additionally, long gestation time required for research and developmental activities as well as the need for a number of essential clinical trials to test drugs adds up to significant expenditure. The limitations posed by high development cost of anti-obesity drugs might hinder the growth of the global weight loss and obesity management market. Moreover, the high cost of surgical procedures, such as gastric bypass surgery, adjustable gastric banding, gastric sleeve surgery and gastric balloon treatment, may also affect the growth of the global weight loss and obesity management market adversely.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-411

The global weight loss and obesity management market is estimated based on product type, and distribution sales. Based on product type, the weight loss and obesity management market has been segmented into drugs and devices.

Drugs product type segment is further segmented into GLP-1 receptor agonists, lipase inhibitors, serotonin receptor agonist, a combination drug, and others. Devices product type segment is further segmented into liposuction devices, bariatric stapling devices, gastric band, gastric balloon systems, gastric emptying systems, and gastric electrical stimulation systems.

Devices segment is expected to hold maximum market share in the global weight loss and obesity management market. Based on distribution sales, the weight loss and obesity management market has been segmented into institutional sales and retail sales. In terms of revenue, institutional sales dominated the global weight loss and obesity management market in 2017.

Additional Questions Answered

Some of the additional questions addressed in this report on the weight loss and obesity management market-

• What is the revenue potential of the weight loss and obesity management market across the regions of emerging economies?
• Who are the key competitors in the weight loss and obesity management market and what are their portfolios?
• What are the major challenges influencing the growth of the weight loss and obesity management market?

Segmentation

On the basis of product type

• drugs
• devices

On the basis of distribution sales

• institutional sales
• retail sales

On the basis of geographical

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)
• emerging countries like China, Brazil, and India.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-411

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.